Kura Oncology

Update in progress

KURA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. Its lead product, KOMZIFTI (ziftomenib), is a potent, selective, oral menin inhibitor. Darlifarnib is part of the Phase 1 FIT-001 program, evaluating darlifarnib in combination with other targeted therapies across multiple solid tumors. KO-7246 is a next-generation menin inhibitor explored for diabetes and cardiometabolic disorders and as a combo partner in solid tumors. Headquartered in San Diego, California.

Company score

Sentiment: 0.47; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.34; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.30; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive